Boehringer Ingelheim meets expectations in Q2 2010

Boehringer Ingelheim has posted its financial results for the second quarter of 2010, a period which saw the company meet expectations for the quarter.

As had previously been forecast last year, sales and income declined slightly compared to the corresponding period of 2009, owing to market conditions and a recent increase in research and development investment.

The company expects this expenditure to yield returns in the coming months, having made progress on the development and registration of drugs such as Pradaxa and Twynsta ahead of their planned 2011 launches.

In addition, the firm has been able to progress research into a number of new oncology therapies, as well as slightly increasing its workforce.

It expects that these investments will lead to the achievement of a “high single-digit growth rate” for 2011.

Last month, Boehringer Ingelheim published new clinical data which illustrated the efficacy of a new once-daily indication of its HIV drug Viramune.